Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
REED
3051
DELISTED
Reeds, Inc. Common Stock
REED
| $433K | ﹤0.01% |
2,290
+244
| +12% | +$43K |
|
3052
Marcus & Millichap
MMI
$1.18B
| $432K | ﹤0.01% |
14,000
-124,800
| -90% | -$4.53M |
|
|
CCLP
3053
DELISTED
CSI Compressco LP
CCLP
| $431K | ﹤0.01% |
121,800
-65,499
| -35% | -$212K |
|
|
RRTS
3054
DELISTED
RoadRunner Transportation Systems, Inc.
RRTS
| $431K | ﹤0.01% |
45,088
+30,017
| +199% | +$305K |
|
3055
John B. Sanfilippo & Son
JBSS
$989M
| $430K | ﹤0.01% |
5,400
-7,100
| -57% | -$539K |
|
3056
Bit Digital
BTBT
$520M
| $429K | ﹤0.01% |
+124,000
| New | +$680K |
|
|
GRVY
3057
GRAVITY
GRVY
$489M
| $429K | ﹤0.01% |
+9,300
| New | +$633K |
|
|
TBIO
3058
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $429K | ﹤0.01% |
+34,000
| New | +$358K |
|
3059
Century Aluminum
CENX
$4.59B
| $428K | ﹤0.01% |
62,000
-89,499
| -59% | -$665K |
|
3060
Enlivex Ltd
ENLV
$31M
| $428K | ﹤0.01% |
1,326
+147
| +12% | +$27.1K |
|
3061
CPI Aerostructures
CVU
$75M
| $427K | ﹤0.01% |
50,730
+6,830
| +16% | +$48.2K |
|
3062
First Trust Financials AlphaDEX Fund
FXO
$1.15B
| $427K | ﹤0.01% |
13,500
+5,900
| +78% | +$184K |
|
3063
iShares Core S&P Mid-Cap ETF
IJH
$128B
| $427K | ﹤0.01% |
+11,000
| New | +$422K |
|
|
CKPT
3064
DELISTED
Checkpoint Therapeutics
CKPT
| $426K | ﹤0.01% |
14,070
+1,630
| +13% | +$64K |
|
3065
Clearwater Paper
CLW
$356M
| $425K | ﹤0.01% |
22,975
-56,325
| -71% | -$1.05M |
|
3066
Good Times Restaurants
GTIM
$15.8M
| $421K | ﹤0.01% |
239,453
+2,643
| +1% | +$5.67K |
|
|
CYAN
3067
DELISTED
Cyanotech Corp
CYAN
| $416K | ﹤0.01% |
134,100
+3,100
| +2% | +$9.86K |
|
3068
Eledon Pharmaceuticals
ELDN
$291M
| $414K | ﹤0.01% |
22,748
+11,531
| +103% | +$505K |
|
|
ENG
3069
DELISTED
ENGlobal Corp
ENG
| $413K | ﹤0.01% |
57,345
+1,462
| +3% | +$8.84K |
|
3070
Elastic
ESTC
$8.94B
| $411K | ﹤0.01% |
+5,500
| New | +$449K |
|
3071
Ingles Markets
IMKTA
$1.66B
| $411K | ﹤0.01% |
+13,200
| New | +$388K |
|
3072
Vanguard Industrials ETF
VIS
$8.5B
| $408K | ﹤0.01% |
+2,800
| New | +$399K |
|
|
OIG
3073
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
| $406K | ﹤0.01% |
12,336
+3,697
| +43% | +$158K |
|
|
PRPH
3074
DELISTED
ProPhase Labs
PRPH
| $404K | ﹤0.01% |
18,790
+470
| +3% | +$13.8K |
|
|
CVIA
3075
DELISTED
Covia Holdings Corporation Common Stock
CVIA
| $402K | ﹤0.01% |
+204,900
| New | +$790K |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.